A Phase 1/1b Study of IAM1363 in HER2 Cancers
Recruiting now · Phase 1
Conditions studied: HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
In brief
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Key facts
- Study ID
- NCT06253871
- Run by
- Iambic Therapeutics, Inc
- People needed
- 383
- Starts
- 2024-03-25
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2026-06-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States (enrolling)
- University of Colorado Cancer Center — Aurora, Colorado, United States (enrolling)
- University of Miami — Miami, Florida, United States (enrolling)
- Comprehensive Hematology Oncology — St. Petersburg, Florida, United States (enrolling)
- University of Chicago — Chicago, Illinois, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- University of Michigan — Ann Arbor, Michigan, United States (enrolling)
- Henry Ford Cancer Institute — Detroit, Michigan, United States (enrolling)
- START - Midwest Cancer Research Center — Grand Rapids, Michigan, United States (enrolling)
- Saint Luke's Cancer Institute — Kansas City, Missouri, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Dartmouth Hitchcock Medical — Lebanon, New Hampshire, United States (enrolling)
- Rutgers Cancer Institute — New Brunswick, New Jersey, United States (enrolling)
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
- Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
- University Hospital Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma, United States (enrolling)
- Providence Cancer Institute — Portland, Oregon, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- Vanderbilt Ingram Cancer Center — Nashville, Tennessee, United States (enrolling)
- NEXT Oncology - Austin — Austin, Texas, United States (enrolling)
- Mary Crowley Cancer Research — Dallas, Texas, United States (enrolling)
- UCSD Moores Cancer Center — La Jolla, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.